Improvement of serum lipids and blood pressure during intervention with n‐3 fatty acids was not associated with changes in insulin levels in subjects with combined hyperlipidaemia

Grundt, Heidi; Nilsen, Dennis W.T.; Hetland, Øyvind; Aarsland, Torbjørn; Baksaas, Ingebjørg; Grande, Terje; Woie, Leik

doi:10.1111/j.1365-2796.1995.tb01173.x

Cited by 52 publications

(31 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…n-3 FATTY ACIDS IN MODERATE HYPERTRIGLYCERIDEMIA concentrations in persons with moderate hypertriglyceridemia. Relative to the placebo treatment, fasting triglycerides were reduced by 27% after the 3.4-g/d dose, consistent with previous reports (12,(42)(43)(44)(45)(46). The percentage reduction achieved was related to the subjects' triglyceride concentrations after the placebo dose so that, on average, the subjects with the highest triglycerides achieved the greatest percentage reduction after the higher dose.…”

Section: Discussionsupporting

confidence: 77%

Dose-response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy persons with moderate hypertriglyceridemia

Skulas‐Ray

Kris-Etherton²,

Harris

et al. 2011

The American Journal of Clinical Nutrition

248

161

View full text Add to dashboard Cite

Background: Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have been shown to reduce cardiovascular mortality at a dose of '1 g/d. Studies using higher doses have shown evidence of reduced inflammation and improved endothelial function. Few studies have compared these doses. Objective: The objective of this study was to compare the effects of a nutritional dose of EPA+DHA (0.85 g/d) with those of a pharmaceutical dose (3.4 g/d) on serum triglycerides, inflammatory markers, and endothelial function in healthy subjects with moderately elevated triglycerides. Design: This was a placebo-controlled, double-blind, randomized, 3-period crossover trial (8 wk of treatment, 6 wk of washout) that compared the effects of 0.85 and 3.4 g EPA+DHA/d in 23 men and 3 postmenopausal women with moderate hypertriglyceridemia (150-500 mg/dL). Results: The higher dose of EPA+DHA lowered triglycerides by 27% compared with placebo (mean 6 SEM: 173 6 17.5 compared with 237 6 17.5 mg/dL; P = 0.002), whereas no effect of the lower dose was observed on lipids. No effects on cholesterol (total, LDL, and HDL), endothelial function [as assessed by flow-mediated dilation, peripheral arterial tonometry/EndoPAT (Itamar Medical Ltd, Caesarea, Israel), or Doppler measures of hyperemia], inflammatory markers (interleukin-1b, interleukin-6, tumor necrosis factor-a, and high-sensitivity C-reactive protein), or the expression of inflammatory cytokine genes in isolated lymphocytes were observed. Conclusion: The higher dose (3.4 g/d) of EPA+DHA significantly lowered triglycerides, but neither dose improved endothelial function or inflammatory status over 8 wk in healthy adults with moderate hypertriglyceridemia. The trial was registered at clinicaltrials. gov as NCT00504309.Am J Clin Nutr 2011;93:243-52.

show abstract

Section: Discussionsupporting

confidence: 77%

Dose-response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy persons with moderate hypertriglyceridemia

Skulas‐Ray

Kris-Etherton²,

Harris

et al. 2011

The American Journal of Clinical Nutrition

248

161

View full text Add to dashboard Cite

show abstract

“…The findings of this meta-regression analysis were supported by studies in patients with essential hypertension, 47,93 hypertriglyceridemia, 57 or combined hyperlipidemia, 44,94 patients who had undergone heart transplantation, 95 or hypertensive heart transplant recipients, 48 showing significant reductions in systolic and/or diastolic BP with omega-3 EE given at 2000-6000 mg/day. The reduction of BP may be due to effects on the arterial vascular bed.…”

Section: Blood Pressuresupporting

confidence: 48%

“…20 Omega-3 EE oral administration in healthy volunteers for 12 weeks determined significant dosedependent increases in plasma phospholipid EPA and DHA content. 43 The same increases in plasma/serum phospholipid EPA and DHA content were seen in various patient populations receiving oral omega-3 EE, such as those with combined hyperlipidemia, 44 severe hypertriglyceridemia, 45 CAD, 46 essential hypertension, 47 and hypertensive heart transplant recipients. 48 EPA and DHA concentrations in plasma phospholipids are related to the level of EPA and DHA incorporated into cell membranes.…”

Section: Pharmacokinetic Propertiesmentioning

confidence: 69%

Uses and benefits of omega-3 ethyl esters in patients with cardiovascular disease

Levantesi

Silletta²,

Marchioli³

2010

JMDH

View full text Add to dashboard Cite

Much evidence on the favorable effects of omega-3 ethyl esters on cardiovascular morbidity and mortality has been obtained in studies performed in healthy subjects and in different clinical settings. Here the clinical effects of omega-3 ethyl ester administration in patients with previous myocardial infarction or heart failure are reviewed, together with a discussion of underlying mechanisms of action. The pharmacokinetic and pharmacodynamic properties of omega-3 ethyl esters, as well as evidence concerning their safety and tolerability, are also reported.

show abstract

“…[35][36][37][38][39][40] This study, and others, has not shown detrimental effects, in healthy volunteers, hypertensive or dyslipidaemic subjects or those with diabetes. 36,41,42 In obese hyperinsulinaemic women, we found there are no adverse effects of LC n-3 PUFA on glucose, HbA1c or insulin sensitivity either during weight-loss or in a stable weightreduced state. Moreover, there was a significant reduction glucose excursion during the OGTT in both the WLFO and WLPO groups.…”

Section: Discussionmentioning

confidence: 69%

Additive benefits of long-chain n-3 polyunsaturated fatty acids and weight-loss in the management of cardiovascular disease risk in overweight hyperinsulinaemic women

et al. 2006

View full text Add to dashboard Cite

Background: Obesity, inflammation, insulin resistance and cardiovascular disease (CVD) risk are inter-related. Both weight-loss and long-chain n-3 polyunsaturated fatty acids (LC n-3 PUFA) are independently known to reduce metabolic risk, but the combined effects are unclear.Objective: This study examines whether addition of LC n-3 PUFA to a low fat/high carbohydrate weight-loss programme results in greater improvements in inflammation, insulin sensitivity and CVD risk, than weight-loss alone. Design: One hundred and sixteen overweight insulin-resistant women entered a 24-week randomised intervention study. Thirty-nine women were randomised to a weight-loss programme, with LC n-3 PUFA (WLFO), 38 to a weight-loss programme with placebo oil (WLPO), and 39 to receive placebo oil, with no weight-loss programme (control). Results: Ninety-three women completed the study (35 WLFO, 32 WLPO and 26 control), with significant weight-loss in WLFO (10.871.0%) and WLPO (12.471.0%) compared to the control group (Po0.0001). The WLFO, but not WLPO or control group, showed significant increases in adipose tissue LC n-3 PUFA (0.3470.20 vs 0.1770.10 and 0.1670.10 %DHA, Po0.0001). Weight-loss showed significant improvements in insulin sensitivity (Po0.001), lipid profile (triglycerides Po0.05) and inflammation (sialic acid Po0.05). Time * group effects showed significant decreases in triglycerides (Po0.05) and increases in adiponectin (Po0.01) with LC n-3 PUFA, in the WLFO vs WLPO groups. Conclusions: Weight-loss improved risk factors associated with CVD, with some additional benefits of LC n-3 PUFA on triglycerides and adiponectin. Given the current low dietary intake of LC n-3 PUFA, greater attention should be given to increase these fatty acids in the treatment of obesity.

show abstract

Improvement of serum lipids and blood pressure during intervention with n‐3 fatty acids was not associated with changes in insulin levels in subjects with combined hyperlipidaemia

Abstract: The atherogenic risk profile was improved with K85 in subjects with combined hyperlipidaemia, but n-3 fatty acids supplementation did not affect glucose/insulin homeostasis.

Cited by 52 publications

References 27 publications

Dose-response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy persons with moderate hypertriglyceridemia

Dose-response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy persons with moderate hypertriglyceridemia

Uses and benefits of omega-3 ethyl esters in patients with cardiovascular disease

Additive benefits of long-chain n-3 polyunsaturated fatty acids and weight-loss in the management of cardiovascular disease risk in overweight hyperinsulinaemic women

Contact Info

Product

Resources

About